GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
80.98
-0.19 (-0.23%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close81.17
Open81.30
Bid80.98 x 400
Ask81.11 x 200
Day's Range80.37 - 81.53
52 Week Range63.76 - 86.27
Volume7,920,878
Avg. Volume8,227,544
Market Cap105.782B
Beta0.87
PE Ratio (TTM)9.22
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (2.56%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Gilead Collaborates with Pfizer for Yescarta Combo Study
    Zacks2 days ago

    Gilead Collaborates with Pfizer for Yescarta Combo Study

    Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

  • GuruFocus.com2 days ago

    CVS and Gilead Sciences Hit the Casualty List

    Starving in the midst of plenty, some stocks got roughed up in the fourth quarter even as the market rose

  • Which Biotech Stocks Could Surprise To The Upside On Earnings?
    Investor's Business Daily2 days ago

    Which Biotech Stocks Could Surprise To The Upside On Earnings?

    Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.

  • Barrons.com2 days ago

    Gilead Earnings: Don't Get Too Excited

    Shares of Gilead Sciences (GILD) didn't have a great 2017, and analysts are split on whether or not the stock will find its footing  this year, as biotech stocks face a challenging 2018. Guggenheim's Tony Bulter and his team reiterated a Neutral rating on Gilead Friday, as part of their biotech earnings preview. Butler writes that  its eroding Hepatitis C (HCV) drug sales continues to impact earnings, but that those declines could start to bottom out in the second half of this year.

  • Merck & Co.’s Human Vaccines Business in 3Q17
    Market Realist2 days ago

    Merck & Co.’s Human Vaccines Business in 3Q17

    Who’s Watching Merck & Co. in January 2018?

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug
    Market Realist2 days ago

    Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug

    Who’s Watching Merck & Co. in January 2018?

  • InvestorPlace2 days ago

    Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive

    Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. The rumored price for Juno would be $10-12 billion, not a big deal when Celgene is worth $80 billion, but Juno was only worth $5.6 billion on Jan. 12.

  • Motley Fool3 days ago

    Healthcare: Is Celgene Going to Buy Juno Therapeutics?

    A big biotech merger could be in the works.

  • Merck & Co., Inc. Stock Could Still Soar Another 10% From Here
    InvestorPlace3 days ago

    Merck & Co., Inc. Stock Could Still Soar Another 10% From Here

    While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.

  • 3 Top-Ranked Drug Stocks That Are Broker Favorites
    InvestorPlace3 days ago

    3 Top-Ranked Drug Stocks That Are Broker Favorites

    Pharma and biotech stocks made an impressive comeback in 2017 with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.7% and 11.8%, respectively. Immuno-oncology remains a key focus area with Gilead acquiring Kite last year for $11.9 billion and Celgene Corporation (NASDAQ:CELG) currently rumored to be interested in acquiring Juno Therapeutics Inc (NASDAQ:JUNO).

  • InvestorPlace3 days ago

    No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop

    Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.

  • What's Juno Therapeutics Worth to Celgene?
    Motley Fool4 days ago

    What's Juno Therapeutics Worth to Celgene?

    Celgene may be considering a multibillion-dollar bid to acquire Juno.

  • Reuters4 days ago

    Florida man gets prison for trading on tip about Gilead deal

    Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Florida man gets prison for trading on tip about Gilead deal
    Reuters4 days ago

    Florida man gets prison for trading on tip about Gilead deal

    A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said. Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Investopedia4 days ago

    How a Juno Takeover Could Boost Celgene

    If Celgene acquires Juno Therapeutics, it could expand its cancer-drug pipeline, opening up new revenue streams.

  • Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense
    Investor's Business Daily4 days ago

    Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense

    Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.

  • Why Juno Therapeutics Stock Is Soaring Today
    Motley Fool4 days ago

    Why Juno Therapeutics Stock Is Soaring Today

    The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.

  • Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
    Zacks4 days ago

    Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

    There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

  • Is Gilead Sciences, Inc. a Buy in 2018?
    Motley Fool4 days ago

    Is Gilead Sciences, Inc. a Buy in 2018?

    Focus on the future rather than the past for this big biotech.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Barrons.com5 days ago

    Gilead: Finally an Upgrade!

    Shares of Gilead Sciences (GILD) underperformed in 2017, and analysts are split on whether to get slightly more optimistic about the stock, while others argue that 2018 won't be its year either.  Count Wells Fargo's Jim Birchenough and his team among the former. Birchenough writes that he's more confident in the stability of Hepatitis C trends this year, with an expectation of trough earnings in 2019, followed by multiple expansion on growth beyond that year.

  • Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
    Market Realist5 days ago

    Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.

  • Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
    Market Realist5 days ago

    Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018?

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist5 days ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.